Skip to Content

'
Laura L. Worth, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1990 University of Texas Medical School, Houston, TX, MD, Medicine
1990 Graduate School of Biological Sciences, Houston, TX, PHD, Doctorate of Philosophy
1983 Smith College, Northampton, MA, BA, Arts

Postgraduate Training

7/1994-6/1998 Pediatric Hematology/Oncology Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1993-6/1994 Post Doctorate, Molecular Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1990-6/1994 Pediatric Intern and Resident, University of Texas Health Science Center, Houston, TX

Experience/Service

Academic Appointments

Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-present

Administrative Appointments/Responsibilities

Center Medical Director, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-present
Clinical Director, Cell Therapy, Division of Clinical Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-present

Other Appointments/Responsibilities

Member, Children's Cancer Hospital Planning Committee, The University of Texas MD Anderson Cancer Center, Houston, 1/2008-present

Institutional Committee Activities

Chair, Conflict of Interest Committee, 2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, Mcmannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, <b>Worth L</b>, Qazilbash MH, Korbling M, Rondon G, Ciuerea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. New England Journal of Medicine 367(24):2305-15, 12/2013.
2. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 5/2013. e-Pub 10/2012. PMID: 23085830.
3. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. PMID: 23234514.
4. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 11/2012. e-Pub 5/2012. PMCID: PMC4010147.
5. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 4/2012. e-Pub 8/23/2011. PMID: 21867666.
6. Harting MT, Baumgartner JE, Worth LL, Ewing-Cobbs L, Gee AP, Day MC, Cox CS. Cell therapies for traumatic brain injury. Neurosurg Focus 24(3-4):E18, 2008. PMID: 18341394.
7. Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 86(6):324-33, 11/2007. PMID: 18004177.
8. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13(15 Pt 1):4503-10, 8/2007. PMID: 17671136.
9. Komanduri K, Worth LL, St. John L, de Lima M,McMannis J,Rosinski S, McNiece I,Bryany S, Kaur I, Martin S, Wieder E, Cooper L, Petropoulos D, Molldrem J, Champlin R, Shpall E. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. BLOOD 110(13):4543-51, 2007.
10. Huang G, Mills L, Worth LL. Expression of human glutathione S-transferase P1 mediates chemosensitivity of osteosarcoma cells. Molecular Cancer Therapeutics 5(5):1610-9, 2007.
11. Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RC, Chan KW. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoetic stem cell transplantation for advanced pediatric hematological malignancies. Bone Marrow Transplant, 37; 463-7, 2006. 37:463-7, 2006.

Grant & Contract Support

Title: Propogate and evaluate umbilical cord blood derived polyclonal effector T-Cells
Funding Source: J.P. McCarthy Fund Developmnetal Grant Program Award
Role: Project Leader
Duration: 10/2006 - 10/2007
 
Title: Gene therapy with IL-12 and the eradication of metastatic pulmonary osteosarcoma: Role of NK and T cells
Funding Source: National Institute of Health/National Cancer Institute
Role: Principal Investigator
Duration: 8/1/2002 - 7/1/2007
 
Title: Gene therapy with IL-12 and the eradication of metastatic pulmonary osteosarcoma: Role of NK and T cells - Physician Scientist Award
Funding Source: University of Texas M.D Anderson Cancer Center
Role: Principal Investigator
Duration: 8/1/2002 - 7/1/2005

Last updated: 7/2/2014